EMD Chemicals Signs License with Luminex to Develop Assays for xMAP

Dec 10, 2007

NEW YORK (GenomeWeb News) - Luminex has granted EMD Chemicals, a subsidiary of Germany’s Merck KGaA, a license to develop multiplex immunoassays for the xMAP technology platform, EMD said last week.

EMD said it plans to develop multiplex assays for the xMAP under its Novagen brand to detect the phosphorylation status of proteins in disease-related signaling pathways.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

To Control the Spread

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

More to Do

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

'Follow Me to Maryland'

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.

This Week in PLOS

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Main menu